123ArticleOnline Logo
Welcome to 123ArticleOnline.com!
ALL >> General >> View Article

Rznomics: Circular Rna Platform Tech

Profile Picture
By Author: Ben Gross
Total Articles: 433
Comment this article
Facebook ShareTwitter ShareGoogle+ ShareTwitter Share

Rznomics, a biopharmaceutical company, has developed a groundbreaking 'self-circularized RNA structure' platform technology that efficiently generates circular RNA, overcoming the limitations of existing methods.

Circular RNA (circRNA) offers improved stability against nucleases and minimal unwanted immune responses, making it an attractive candidate for vaccines and therapeutics. Rznomics' technology utilizes a unique Tetrahymena trans-splicing ribozyme platform to convert linear RNA into circular RNA through an end-to-end self-targeting and splicing (STS) reaction. Unlike other methods, Rznomics' circularization does not leave unnecessary genetic information in the gene of interest (GOI). The efficiency of the self-circularization process is comparable to other methods, and various optimization strategies can be employed to increase its efficacy, even with long RNA molecules.

The significance of Rznomics' technology lies in its potential for commercialization, enabling more competitive pricing for circRNA vaccines or therapeutics while maintaining efficacy. In vitro transcription initiates the self-circularization ...
... reaction simultaneously, streamlining the purification process. The purified circRNA demonstrates sustained protein expression without unwanted immune responses, outperforming linear RNA with modified nucleotides.

The research was supported by the Ministry of Science & ICT and the National Research Foundation of Korea. Rznomics holds a patent for the 'Self-circularization RNA structure and Platform technology' in South Korea, with applications submitted in the U.S. and other major countries.

Rznomics is a biopharmaceutical company focused on RNA-based gene therapeutic bio-drugs for cancer and incurable diseases. Their core platform technology utilizes an RNA replacement enzyme, trans-splicing ribozyme, to selectively induce therapeutic gene activity in cells expressing target RNA. The company's lead candidate, RZ-001, is intended for treating Hepatocellular Carcinoma & Glioblastoma, with other treatments in the pipeline for Alzheimer's disease and hereditary retinal dystrophy.

More Information : https://www.techdogs.com/tech-news/pr-newswire/rznomics-presents-its-own-circular-rna-platform-technology

Total Views: 115Word Count: 272See All articles From Author

Add Comment

General Articles

1. International School In Malaysia | Top International School In Malaysia
Author: elisha

2. Sonofitâ„¢ | Uk Official | #1 New Hearing Formula
Author: rajesh

3. Essential Benefits Of Digital Marketing Efforts
Author: Anthea Johnson

4. Dissatisfaction Of Even Old-time Customers With Amazon India
Author: Yash Kumar

5. Vidmate App Download For Android
Author: vidmate app

6. Finding The Best Seo Company In Mumbai
Author: Siddhi Dheniya

7. Melasma Laser Treatment For Smooth And Even Skin Tone
Author: pavitra

8. Winter Beauty Package At La Femme Hair, Skin & Bridal Salon At La Femme In Satellite, Ahmedabad
Author: lafemmeindia

9. How To Get Your Clients To Make Faster Payments?
Author: Invoice Temple

10. Discover Why We Are The Best Multispeciality Hospital In Jaipur
Author: YATIKA

11. Gutters, Roofing, Windows, And Sidings | What Comes First?
Author: Gutter Empire LLC

12. The Role Of Technology In Outstation Taxi Bookings
Author: RIDEXPRESS

13. Crystalline Designers
Author: Crystalline

14. Wpc Outdoor Wall Panels
Author: karthik

15. The Importance Of Pharma Hcp Engagement In Modern Healthcare
Author: Jesvira

Login To Account
Login Email:
Password:
Forgot Password?
New User?
Sign Up Newsletter
Email Address: